10x Genomics (TXG) Liabilities and Shareholders Equity (2018 - 2026)

10x Genomics has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $1.0 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 5.11% year-over-year to $1.0 billion; the TTM figure through Jun 2026 stood at $4.1 billion (up 10.02% YoY), while the FY2025 annual figure was $1.0 billion, up 13.36% from the prior year.
• Liabilities and Shareholders Equity came in at $1.0 billion for Q2 2026 at 10x Genomics, up from $1.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $903.4 million in Q1 2025.
• Average Liabilities and Shareholders Equity over 5 years is $980.8 million, with a median of $992.9 million recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity retreated 8.99% in 2024 and climbed 13.36% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.0 billion in 2022, then slipped by 6.2% to $965.1 million in 2023, then decreased by 4.82% to $918.6 million in 2024, then rose by 13.36% to $1.0 billion in 2025, then decreased by 1.09% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.0 billion in Q2 2026, $1.0 billion in Q1 2026, and $1.0 billion in Q4 2025.